DDL 2018 Mpac Langen

Highlights from DDL 2018

The annual Drug Delivery to the Lungs (DDL) meeting drew a record-breaking number of visitors to the Edinburgh International Conference Centre. We were one of over 100 exhibitors and 850 delegates who attended the three-day conference. Read our report on this exceptionally interesting pharmaceutical event below.

Expert speakers, knowledge-sharing and industry-leading exhibitors

Drug Delivery to the Lungs (DDL) is widely recognised as Europe’s premier conference and industry exhibition for pulmonary and nasal drug delivery. Its official mission is “to provide a vehicle for the advancement of respiratory science and to share recent developments in inhalation therapy in a friendly and informal environment.”

As regular exhibitors at this event, we have found it provides an invaluable window into this specialist field of drug delivery. Mixing with scientists, academics, clinicians, regulators and industry experts with a common purpose, means we benefit from first-hand insights into the issues and challenges driving developments.

A packed programme of presentations covered five session themes. This year’s commemorative DDL lecture was delivered by Reinhard Vehring of the University of Alberta and, with two award schemes in place to highlight the work of talented junior researchers and emerging scientists, DDL 2018 certainly didn’t disappoint.

Industry talking points

We heard from a number of different voices on a broad range of topics – many of which were followed by animated discussions during the Q&A sessions.

Several of the talks focused on the need for OINDP (orally inhaled and nasal drug product) specialists to deal with the inherent complexities of aerosol drug delivery better. Greater understanding was also called for on how characteristics differ between types so that more successful therapies can be developed.

One issue that drew conflicting opinion was the suggestion that the proliferation of different inhalers had done little to improve adherence or outcomes, so industry should work harder to standardise devices and simplify patient communication. Interestingly, this message received a certain amount of push-back, with the need to address patient and clinician concerns to regulators put forward as a more effective strategy.

Product innovation

The exhibitor area brought together an impressive number of companies of all sizes to share the latest product developments with this specialist audience.

Mpac took the opportunity to highlight two of our market-leading, special purpose systems. They are designed for automating the manufacture of your pharmaceutical drug deliver solutions through to mass production. Both provide consistent and accurate dosing technology throughout the drug development cycle:

  • μ-fill labscale: an easy-to-use, semi-automated benchtop instrument for accurate powder micro-dosing into the pre-formed blisters used typically in dry powder inhaler devices (DPIs).
  • μ-check: an innovative and easy-to-use automatic system designed to weigh the contents of individual powder filled blister cavities in a controlled, accurate and repeatable way.

We are delighted to report that both systems attracted positive attention, discussion and interest. As always, we welcomed every comment and question as they help ensure our special purpose, dosing technology remains relevant to current – and future – needs of the global pharmaceutical market.

Mpac designs and develops innovative machinery to automate the manufacture of your drug delivery solution. Please get in touch to find out more about how our creative engineering team can help bring your product to market.

 

 

Posted by Simon Mason